Structural and non-coding variants increase the diagnostic yield of clinical whole genome sequencing for rare diseases.
Pagnamenta AT., Camps C., Giacopuzzi E., Taylor JM., Hashim M., Calpena E., Kaisaki PJ., Hashimoto A., Yu J., Sanders E., Schwessinger R., Hughes JR., Lunter G., Dreau H., Ferla M., Lange L., Kesim Y., Ragoussis V., Vavoulis DV., Allroggen H., Ansorge O., Babbs C., Banka S., Baños-Piñero B., Beeson D., Ben-Ami T., Bennett DL., Bento C., Blair E., Brasch-Andersen C., Bull KR., Cario H., Cilliers D., Conti V., Davies EG., Dhalla F., Dacal BD., Dong Y., Dunford JE., Guerrini R., Harris AL., Hartley J., Hollander G., Javaid K., Kane M., Kelly D., Kelly D., Knight SJL., Kreins AY., Kvikstad EM., Langman CB., Lester T., Lines KE., Lord SR., Lu X., Mansour S., Manzur A., Maroofian R., Marsden B., Mason J., McGowan SJ., Mei D., Mlcochova H., Murakami Y., Németh AH., Okoli S., Ormondroyd E., Ousager LB., Palace J., Patel SY., Pentony MM., Pugh C., Rad A., Ramesh A., Riva SG., Roberts I., Roy N., Salminen O., Schilling KD., Scott C., Sen A., Smith C., Stevenson M., Thakker RV., Twigg SRF., Uhlig HH., van Wijk R., Vona B., Wall S., Wang J., Watkins H., Zak J., Schuh AH., Kini U., Wilkie AOM., Popitsch N., Taylor JC.
BACKGROUND: Whole genome sequencing is increasingly being used for the diagnosis of patients with rare diseases. However, the diagnostic yields of many studies, particularly those conducted in a healthcare setting, are often disappointingly low, at 25-30%. This is in part because although entire genomes are sequenced, analysis is often confined to in silico gene panels or coding regions of the genome. METHODS: We undertook WGS on a cohort of 122 unrelated rare disease patients and their relatives (300 genomes) who had been pre-screened by gene panels or arrays. Patients were recruited from a broad spectrum of clinical specialties. We applied a bioinformatics pipeline that would allow comprehensive analysis of all variant types. We combined established bioinformatics tools for phenotypic and genomic analysis with our novel algorithms (SVRare, ALTSPLICE and GREEN-DB) to detect and annotate structural, splice site and non-coding variants. RESULTS: Our diagnostic yield was 43/122 cases (35%), although 47/122 cases (39%) were considered solved when considering novel candidate genes with supporting functional data into account. Structural, splice site and deep intronic variants contributed to 20/47 (43%) of our solved cases. Five genes that are novel, or were novel at the time of discovery, were identified, whilst a further three genes are putative novel disease genes with evidence of causality. We identified variants of uncertain significance in a further fourteen candidate genes. The phenotypic spectrum associated with RMND1 was expanded to include polymicrogyria. Two patients with secondary findings in FBN1 and KCNQ1 were confirmed to have previously unidentified Marfan and long QT syndromes, respectively, and were referred for further clinical interventions. Clinical diagnoses were changed in six patients and treatment adjustments made for eight individuals, which for five patients was considered life-saving. CONCLUSIONS: Genome sequencing is increasingly being considered as a first-line genetic test in routine clinical settings and can make a substantial contribution to rapidly identifying a causal aetiology for many patients, shortening their diagnostic odyssey. We have demonstrated that structural, splice site and intronic variants make a significant contribution to diagnostic yield and that comprehensive analysis of the entire genome is essential to maximise the value of clinical genome sequencing.